# Aprepitant Triple Therapy for the Prevention of CINV in Nondrinking and Young Women Who Received Moderately Emetogenic Chemotherapy

> **NCT03674294** · PHASE3 · COMPLETED · sponsor: **Sun Yat-sen University** · enrollment: 248 (actual)

## Conditions studied

- Gastrointestinal Neoplasms
- Chemotherapy-induced Nausea and Vomiting

## Interventions

- **DRUG:** Aprepitant
- **DRUG:** Palonosetron
- **DRUG:** Dexamethasone
- **DRUG:** Placebo Oral Tablet

## Key facts

- **NCT ID:** NCT03674294
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-08-04
- **Primary completion:** 2020-03-31
- **Final completion:** 2020-06-01
- **Target enrollment:** 248 (ACTUAL)
- **Last updated:** 2023-02-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03674294

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03674294, "Aprepitant Triple Therapy for the Prevention of CINV in Nondrinking and Young Women Who Received Moderately Emetogenic Chemotherapy". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03674294. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*